This AI Biotech Stock Is Already Profitable. Should You Buy It?
As you may have heard amid the recent hype surrounding artificial intelligence (AI), Schrödinger (NASDAQ: SDGR) is one of the leading biotech companies using machine learning and AI to discover new drugs, and it might be the only one with a claim to being profitable in this pursuit. It's undeniable that investors are interested thanks to its position in a cutting-edge field -- and the stock is up 50% so far this year.
But does that mean you should add it to your portfolio in the hopes of capturing significant growth as it matures? Let's investigate how it's actually performing, as well as how it's likely to shape up over the coming years.
Before you buy shares of Schrödinger, it's important to recognize that its top- and bottom-line growth are far from assured in the near-term.
Source Fool.com
